课题基金 / 基金详情

ALZHEIMER'S IN LONG TERM PROPRANOLOL FOR AGITATION

ALZHEIMER'S IN LONG TERM PROPRANOLOL FOR AGITATION
阿尔茨海默氏症长期服用普萘洛尔治疗躁动
批准号:
6372533
负责人:
ELAINE R. PESKIND
金额:
$31.11万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-09-01 至 2004-08-31

项目摘要

项目成果

ELAINE R. PESKIND的其他基金

相似基金

相关文献

中文摘要
翻译
破坏性激动行为经常发生在阿尔茨海默病(AD),特别是在养老院居民。 这些问题行为经常沉淀养老院安置,并继续造成病人的痛苦和干扰必要的护理在养老院设置。 有限的临床试验数据表明,抗精神病药物和其他精神药物对这些问题的疗效有限,副作用很大。 对这些问题行为进行药物治疗的新方法将是有益的。最近的研究表明AD患者对中枢神经系统(CNS)去甲肾上腺素能刺激的行为敏感性增加,并且在AD的晚期阶段CNS去甲肾上腺素能流出增加。这些中枢神经系统的去甲肾上腺素能特性可能有助于表达的破坏性激越行为在AD。 普萘洛尔是一种β-肾上腺素能拮抗剂药物,可降低对CNS去甲肾上腺素能刺激的反应性。 轶事报告和我们的初步研究结果表明,心得安减少AD的破坏性激动行为。 本提案的主要目的是评估普萘洛尔在管理养老院AD患者破坏性激越行为中的有效性和安全性。 受试者将在一项为期8周的平行设计、双盲试验中随机接受普萘洛尔(最大剂量120 mg/天)或安慰剂。 主要结局指标为临床总体印象变化评分和简明精神病评定量表和神经精神量表从基线至末次观察的变化评分。 还将评估认知、功能状态和不良事件。第二个目标是评估去甲肾上腺素流出和去甲肾上腺素刺激的敏感性作为普萘洛尔治疗反应的预测因子。 尽管在拟定的治疗试验中测量CNS去甲肾上腺素能流出或CNS肾上腺素能受体不可行,但血浆去甲肾上腺素(NE)和淋巴细胞β-肾上腺素能受体密度、亲和力和灵敏度的测量分别提供了去甲肾上腺素能流出和β-肾上腺素能受体状态的可实现估计值。 我们将确定是否高血浆NE和/或高淋巴细胞β-肾上腺素能受体密度、亲和力和/或敏感性定义了对普萘洛尔最敏感的分裂性激越AD患者。
英文摘要
Disruptive agitated behaviors frequently occur in Alzheimer's disease (AD), particularly among nursing home residents. These problem behaviors frequently precipitate nursing home placement and continue to cause patient distress and interfere with necessary care in the nursing home setting. Limited clinical trial data available suggest only modest efficacy and substantial adverse effects for antipsychotic and other psychotropic drugs prescribed for these problems. New approaches to pharmacologic treatment of these problem behaviors would be beneficial. Recent studies suggest increased behavioral sensitivity to central nervous system (CNS) noradrenergic stimulation in AD, and increased CNS noradrenergic outflow in the advanced stages of AD. These CNS noradrenergic characteristics may contribute to the expression of disruptive agitated behaviors in AD. Propranolol is a beta-adrenergic antagonist drug that decreases responsiveness to CNS noradrenergic stimulation. Anecdotal reports and our preliminary findings suggest propranolol decreases disruptive agitated behaviors in AD. The primary goal of this proposal is to evaluate the efficacy and safety of propranolol in the management of disruptive agitated behaviors in nursing home patients with AD. Subjects will be randomized to propranolol (maximum dose 120 mg per day) or placebo in an 8-week parallel design, double-blind trial. Primary outcome measures will be Clinical Global Impression of Change score and change scores from baseline to last observation on the Brief Psychiatric Rating Scale and Neuropsychiatric Inventory. Cognition, functional status, and adverse events will also be assessed. A secondary goal is to evaluate noradrenergic outflow and sensitivity to noradrenergic stimulation as predictors of therapeutic response to propranolol. Although measuring CNS noradrenergic outflow or CNS adrenergic receptors is not feasible in the proposed treatment trial, measurements of plasma norepinephrine (NE) and lymphocyte beta-adrenergic receptor density, affinity, and sensitivity provide achievable estimates of noradrenergic outflow and beta-adrenergic receptor status respectively. We will determine if high plasma NE and/or high lymphocyte beta-adrenergic receptor density, affinity, and/or sensitivity define AD patients with disruptive agitation most responsive to propranolol.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the Role of Post-TBI Sleep Disruption in the Development of CTE and Alzheimer's Disease-Related Neuropathology
Mild TBI and Biomarkers of Neurodegeneration
  • 批准号:
    10490311
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2019
  • 负责人:
    ELAINE R. PESKIND
  • 依托单位:
Mild TBI and Biomarkers of Neurodegeneration
  • 批准号:
    10269890
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2019
  • 负责人:
    ELAINE R. PESKIND
  • 依托单位:
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease
  • 批准号:
    9265401
  • 项目类别:
  • 资助金额:
    $33.25万
  • 财政年份:
    2016
  • 负责人:
    ELAINE R. PESKIND
  • 依托单位:
海外基金